FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Greenway Schond L.		 2. Issuer Name and Ticker or Trading Symbol

Mind Medicine (MindMed) Inc. [ MNMD ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Financial Officer
(Last)          (First)          (Middle)

C/O MIND MEDICINE (MINDMED), INC., ONE WORLD TRADE CENTER, SUITE 8500		 3. Date of Earliest Transaction (MM/DD/YYYY)

5/23/2022
(Street)

NEW YORK, NY 10007
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

5/23/2022 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Subordinate Voting Shares 5/23/2022  A  1270000 (1)A$0.00 1270000 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) $0.78 (2)5/23/2022  A   1650000     (3)5/22/2027 Subordinate Voting Shares 1650000 $0.00 1650000 D  
Explanation of Responses:
(1) These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one subordinate voting share of the Issuer. Of these RSUs, 25% shall vest on May 23, 2023 with 1/12th of the remaining shares vesting each quarter thereafter over 12 quarters, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date.
(2) The option grant has an exercise price of $1.00 Canadian Dollars. This represents the exercise price in United States Dollars.
(3) The shares subject to the option vest and become exercisable, with 25% vesting on May 23, 2023, and 1/36th of the remaining shares vesting monthly thereafter over 36 months, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date.

Remarks:
Explanatory Note: This Amendment on Form 4/A is being filed to amend the Form 4 filed on May 23, 2022 solely to update the Exercise Price of the Stock Option in Table 2 and Explanation of Responses 2.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Greenway Schond L.
C/O MIND MEDICINE (MINDMED), INC.
ONE WORLD TRADE CENTER, SUITE 8500
NEW YORK, NY 10007

Chief Financial Officer
Signatures
/s/ Schond L. Greenway6/3/2022
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Mind Medicine MindMed (NASDAQ:MNMD)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Mind Medicine MindMed Charts.
Mind Medicine MindMed (NASDAQ:MNMD)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Mind Medicine MindMed Charts.